Adult Dosing
Alpha1-antitrypsin deficiency
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Possibility for development of severe hypersensitivity and anaphylactic reactions exist more in patients with selective or severe IgA deficiency and with known antibodies to IgA. Continuously monitor vital signs and carefully observe patients throughout the infusion. Immediately discontinue infusion on development of anaphylactic or severe anaphylactoid reactions. Epinephrine and other appropriate supportive therapy should be readily available for the treatment of any acute anaphylactic or anaphylactoid reaction
- Therapy is associated with the risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD). Screen plasma donors for prior exposure to certain viruses for minimizing the risk of transmitting an infectious agent. Despite these measures, potential for transmitting human pathogenic agents may still exist. Weigh the benefits/risks associated with the use of this product and discuss the risks and benefits with the patient
Caution: Use cautiously in
- Patients at risk for circulatory overload
Supplemental Patient Information
- Inform patients of the early signs of hypersensitivity reactions such as hives, chest tightness, dyspnea, faintness, generalized urticaria, wheezing, hypotension, and anaphylaxis; advise patients to discontinue therapy and contact their physician if such symptoms occur
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer advises caution.
